Trial Profile
A Non-randomized Phase II Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications Adenocarcinoma; Carcinoma; Head and neck cancer; Salivary gland cancer
- Focus Therapeutic Use
- 01 Oct 2019 Status changed to completed, according to the results presented at the 44th European Society for Medical Oncology Congress.
- 24 Jul 2018 New trial record